A Phase 3 interventional study of Lupron (leuprolide acetate) in Puberty, Precocious, sponsored by Abbott. Completed at 9 sites in United States. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2011-04-12.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.
Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 10th largest by enrollment, is the only one that started in 1991, is one of 6 in phase 3, and was the 2nd registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:
LG Chem · Sites in Korea, Republic of
Ages up to 10
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 4–10
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: Up to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 1991.
This study's enrollment of 55 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 68 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 2 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing leuprolide in Puberty, Precocious, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after therapy is discontinued.
This study includes a Prestudy Period; a treatment period where subjects will receive treatment every 4 weeks until the initiation of puberty (age 12 for males and age 11 for females); a follow-up period where subjects will be observed every 6 months until physical and laboratory observations are at pubertal levels, then every 12 months for 5 years; lastly a final follow-up questionnaire is given to all subjects when they are at least 18 years old.
At the treatment visits, efficacy assessments are Tanner staging (suppression of breast development in females and genital development in males), gonadotropins (LH and FSH), sex steroids (estradiol in females and testosterone in males), ratio of bone age to chronological age, adult height compared to a standard population and predicted mature height, and age and time to regular menses in females. This protocol will also capture data from the final questionnaire about female reproductive status at adulthood including the presence of regular menses and number of pregnancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Lupron (leuprolide acetate)
Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
Also known as: Lupron
Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)
Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).
Time frame: Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)
Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).
Time frame: Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations
Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.
Time frame: Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Mean Stimulated Estradiol Concentrations in Females
Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.
Time frame: Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Mean Stimulated Testosterone Concentrations in Males
Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.
Time frame: Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Mean Ratio of Bone Age to Chronological Age
Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.
Time frame: Week 24 and Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Posttreatment Height (ht.) Compared to Standard Population and as Predicted From Ht. at Baseline (BL)
Height was measured by stadiometer and was standardized for age according to standard growth charts. A standardized score of 0 indicated a mean ht. equivalent to mean of a standard population from 2000 CDC standardized ht. charts. Height gain was calculated as ht. - predicted ht. from the Bayley-Pinneau method on the basis of bone age at baseline. Final adult ht. was determined by measurement at final adult ht., if available, or by ht. collected during the follow-up period associated with a growth velocity \<1 cm/year or a bone age \>14 yrs in females or \>15 yrs in males.
Time frame: Final ht. (measured or provided for final questionnaire in subjects >= 18 years of age) or near final adult ht. (<1 cm/year or bone age > 14 years for females or > 15 years for males)
Mean Time to or Mean Age at Regular Menses in Females After Treatment
Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding and was defined by the investigator's clinical judgment.
Time frame: Posttreatment during the follow-up period (subjects observed every 6 months until physical and laboratory observations are at pubertal levels)
Number of Female Subjects Who Reported Regular Menses at Adulthood
Subjects were required to complete final adult questionnaire to provide information on adult reproductive function. Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding.
Time frame: Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)
Number of Subjects Who Reported Pregnancies at Final Questionnaire
The final questionnaire was completed by 20 females who were at least 18 years of age. The subjects reported on total number of pregnancies resulting in live births or number of miscarriages (spontaneous or elective) and whether the subject was currently pregnant.
Time frame: Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)
Number of Pregnancies Reported by Subjects at Final Questionnaire
The final questionnaire was completed by 20 female subjects who were at least 18 years of age. The total number of pregnancies were reported.
Time frame: Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)
| Milestone | Leuprolide Acetate 1 Month Depot |
|---|---|
| Started | 55 |
| Completed | 46 |
| Not completed | 9 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Noncompliance with visit schedule | 3 |
Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).
| Percentage of subjects | Leuprolide Acetate 1 Month Depot |
|---|---|
| Breast development suppression - Week 4 N=44 | 81.8 |
| Breast development suppression-Week 48 N=47 | 80.9 (66.7 to 90.9) |
| Breast development suppression -Week 96 N=41 | 87.8 (73.8 to 95.9) |
| Breast development suppression-Week 144 N=29 | 82.8 (64.2 to 94.2) |
| Breast development suppression - Week 192 N=18 | 66.7 (41.0 to 86.7) |
| Breast development suppression -Week 240 N=13 | 76.9 (46.2 to 95.0) |
| Breast development suppression-Final Visit N=48 | 77.1 |
Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.
| mIU/mL | Leuprolide Acetate 1 Month Depot |
|---|---|
| Peak stimulated LH at Baseline N=55 | 35.0 ± 21.32 |
| Peak stimulated LH at Week 4 N = 55 | 0.8 ± 0.57 |
| Peak stimulated LH at Week 12 N = 54 | 1.1 ± 1.77 |
| Peak stimulated LH at Week 24 N = 53 | 0.8 ± 0.79 |
| Peak stimulated LH at Week 48 N = 54 | 0.6 ± 0.47 |
| Peak stimulated LH at Week 96 N = 46 | 0.4 ± 0.33 |
| Peak stimulated LH at Week 144 N = 36 | 0.4 ± 0.24 |
| Peak stimulated LH at Week 192 N = 20 | 0.4 ± 0.25 |
| Peak stimulated LH at Week 240 N = 17 | 0.4 ± 0.62 |
| Peak stimulated LH at Final Visit N = 55 | 0.8 ± 3.29 |
| Peak stimulated FSH at Baseline N=55 | 13.3 ± 5.58 |
| Peak stimulated FSH at Week 4 N = 55 | 0.9 ± 0.44 |
| Peak stimulated FSH at Week 12 N = 54 | 1.1 ± 0.61 |
| Peak stimulated FSH at Week 24 N = 53 | 1.2 ± 0.84 |
| Peak stimulated FSH at Week 48 N = 54 | 1.2 ± 0.58 |
| Peak stimulated FSH at Week 96 N = 46 | 1.4 ± 0.79 |
| Peak stimulated FSH at Week 144 N = 36 | 1.4 ± 0.73 |
| Peak stimulated FSH at Week 192 N = 20 | 1.3 ± 0.76 |
| Peak stimulated FSH at Week 240 N = 17 | 1.4 ± 0.67 |
| Peak stimulated FSH at Final Visit N = 55 | 1.7 ± 1.73 |
Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.
| pg/mL | Leuprolide Acetate 1 Month Depot |
|---|---|
| Mean stimulated estradiol at baseline N=49 | 15.3 ± 18.73 |
| Mean stimulated estradiol at Week 4 N=48 | 5.0 ± 0.00 |
| Mean stimulated estradiol at Week 12 N=47 | 6.0 ± 6.56 |
| Mean stimulated estradiol at Week 24 N=47 | 5.0 ± 0.00 |
| Mean stimulated estradiol at Week 48 N=47 | 5.0 ± 0.00 |
| Mean stimulated estradiol at Week 96 N=39 | 5.0 ± 0.00 |
| Mean stimulated estradiol at Week 144 N=31 | 5.0 ± 0.00 |
| Mean stimulated estradiol at Week 192 N=15 | 5.0 ± 0.00 |
| Mean stimulated estradiol at Week 240 N=13 | 5.0 ± 0.00 |
| Mean stimulated estradiol at Final Visit N=49 | 5.0 ± 0.14 |
Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.
| ng/dL | Leuprolide Acetate 1 Month Depot |
|---|---|
| Mean stimulated testosterone at baseline N=6 | 347.7 ± 121.86 |
| Mean stimulated testosterone at Week 4 N=6 | 18.0 ± 12.39 |
| Mean stimulated testosterone at Week 12 N=6 | 14.2 ± 7.05 |
| Mean stimulated testosterone at Week 24 N=6 | 13.8 ± 6.15 |
| Mean stimulated testosterone at Week 48 N=6 | 17.3 ± 11.64 |
| Mean stimulated testosterone at Week 96 N=6 | 24.8 ± 19.92 |
| Mean stimulated testosterone at Week 144 N=5 | 21.6 ± 19.50 |
| Mean stimulated testosterone at Week 192 N=4 | 24.0 ± 17.19 |
| Mean stimulated testosterone at Week 240 N=3 | 25.3 ± 24.01 |
| Mean stimulated testosterone at Final Visit N=6 | 24.2 ± 17.16 |
Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.
| ratio | Leuprolide Acetate 1 Month Depot |
|---|---|
| Ratio at Baseline N=53 | 1.5 ± 0.30 |
| Ratio at Week 24 N=53 | 1.5 ± 0.25 |
| Ratio at Week 48 N=51 | 1.4 ± 0.18 |
| Ratio at Week 96 N=44 | 1.3 ± 0.15 |
| Ratio at Week 144 N=31 | 1.2 ± 0.12 |
| Ratio at Week 192 N=26 | 1.2 ± 0.11 |
| Ratio at Week 240 N=16 | 1.2 ± 0.10 |
| Ratio at Final Visit N=53 | 1.2 ± 0.11 |
Height was measured by stadiometer and was standardized for age according to standard growth charts. A standardized score of 0 indicated a mean ht. equivalent to mean of a standard population from 2000 CDC standardized ht. charts. Height gain was calculated as ht. - predicted ht. from the Bayley-Pinneau method on the basis of bone age at baseline. Final adult ht. was determined by measurement at final adult ht., if available, or by ht. collected during the follow-up period associated with a growth velocity \<1 cm/year or a bone age \>14 yrs in females or \>15 yrs in males.
| cm | Leuprolide Acetate 1 Month Depot |
|---|---|
| Near final adult ht. standardized score N=33 | -0.2 ± 1.20 |
| Near final ht.gain from predicted ht. at BL N=29 | 3.2 ± 5.37 |
| Final adult ht.standardized score N=19 | 0.0 ± 1.13 |
| Final adult ht.gain from predicted ht. at BL N=17 | 3.9 ± 5.05 |
Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding and was defined by the investigator's clinical judgment.
| years | Leuprolide Acetate 1 Month Depot |
|---|---|
| Time to regular menses | 1.5 ± 0.53 |
| Age at regular menses | 12.9 ± 0.89 |
Subjects were required to complete final adult questionnaire to provide information on adult reproductive function. Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding.
| Subjects | Leuprolide Acetate 1 Month Depot |
|---|---|
| No. of subjects with regular menses as adults | 16 |
| No. of subjects without regular menses as adults | 4 |
The final questionnaire was completed by 20 females who were at least 18 years of age. The subjects reported on total number of pregnancies resulting in live births or number of miscarriages (spontaneous or elective) and whether the subject was currently pregnant.
| Subjects | Leuprolide Acetate 1 Month Depot |
|---|---|
| Number of subjects who reported being pregnant | 7 |
| Number of subjects who were currently pregnant | 1 |
The final questionnaire was completed by 20 female subjects who were at least 18 years of age. The total number of pregnancies were reported.
| Pregnancies | Leuprolide Acetate 1 Month Depot |
|---|---|
| Number of pregnancies | 12 |
| Number of live births | 6 |
| Number of miscarriages | 5 |
Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).
| Percentage of subjects | Leuprolide Acetate 1 Month Depot |
|---|---|
| Genital development suppression - Week 4 N=5 | 80.0 |
| Genital development suppression - Week 48 N=6 | 83.3 |
| Genital development suppression - Week 96 N=6 | 83.3 |
| Genital development suppression - Week 144 N=4 | 75.0 |
| Genital development suppression - Week 192 N=4 | 75.0 |
| Genital development suppression - Week 240 N=3 | 66.7 |
| Genital development suppression - Final Visit N=6 | 83.3 |
Collected over Each investigator monitored each subject for clinical and laboratory evidence of adverse events at Weeks 4, 8, 12, 24, 36, 48, and then every 6 months until the study drug was discontinued.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprolide Acetate 1 Month Depot | — | 7/55 (12.7%) | 52/55 (94.5%) |
| Event | Leuprolide Acetate 1 Month Depot |
|---|---|
| Aggravation reactionGeneral disorders | 1/55 |
| CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/55 |
| InfectionInfections and infestations | 1/55 |
| Heart arrestCardiac disorders | 1/55 |
| Bone DisorderMusculoskeletal and connective tissue disorders | 1/55 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 1/55 |
| Personality disorderPsychiatric disorders | 1/55 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/55 |
| PneumoniaInfections and infestations | 1/55 |
| Repair of ventriculoperitoneal shuntSurgical and medical procedures | 1/55 |
| Event | Leuprolide Acetate 1 Month Depot |
|---|---|
| PharyngitisInfections and infestations | 29/55 |
| HeadacheNervous system disorders | 25/55 |
| Flu syndromeInfections and infestations | 19/55 |
| RashSkin and subcutaneous tissue disorders | 18/55 |
| Cough increasedRespiratory, thoracic and mediastinal disorders | 17/55 |
| Abdominal painGastrointestinal disorders | 16/55 |
| Accidental injuryInjury, poisoning and procedural complications | 16/55 |
| Emotional LabilityPsychiatric disorders | 15/55 |
| AcneSkin and subcutaneous tissue disorders | 15/55 |
| Otitis mediaInfections and infestations | 15/55 |
| Age, Categorical(Participants) | Leuprolide Acetate 1 Month Depot |
|---|---|
| <=18 years | 55 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age Continuous(years) | Leuprolide Acetate 1 Month Depot |
|---|---|
| Mean | 6.9 ± 1.86 |
| Sex: Female, Male(Participants) | Leuprolide Acetate 1 Month Depot |
|---|---|
| Female | 49 |
| Male | 6 |
| Region of Enrollment(subjects) | Leuprolide Acetate 1 Month Depot |
|---|---|
| United States | 55 |
The record gives a start of Jan 1991, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide